| scholarly article | Q13442814 |
| P2093 | author name string | B A Zonnenberg | |
| C M Schaefer-Prokop | |||
| M Prokop | |||
| T Stijnen | |||
| M E A P M Adriaensen | |||
| D A C Duyndam | |||
| P2860 | cites work | MR imaging of intracranial tuberous sclerosis | Q28299192 |
| Subependymal giant cell tumors in tuberous sclerosis complex | Q34552158 | ||
| Causes of Death in Patients With Tuberous Sclerosis | Q34794286 | ||
| Tuberous Sclerosis Comparison of Computed Tomography and Conventional Neuroradiology | Q48192891 | ||
| P433 | issue | 6 | |
| P921 | main subject | patient | Q181600 |
| tuberous sclerosis | Q1362721 | ||
| P304 | page(s) | 691-696 | |
| P577 | publication date | 2009-02-19 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature | |
| P478 | volume | 16 |
| Q92819914 | A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC) |
| Q38007867 | Advances in the management of subependymal giant cell astrocytoma |
| Q37374350 | Assisting a child with tuberous sclerosis complex (TSC): a qualitative deep analysis of parents' experience and caring needs. |
| Q35836319 | Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex |
| Q92106127 | Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex |
| Q38939596 | Confounding of the Association between Radiation Exposure from CT Scans and Risk of Leukemia and Brain Tumors by Cancer Susceptibility Syndromes |
| Q34468812 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| Q96225008 | Congenital subpendymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome |
| Q48199876 | Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). |
| Q40267839 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. |
| Q91832610 | Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex |
| Q38066584 | Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| Q37806773 | Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis |
| Q38279723 | Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study |
| Q37337337 | Everolimus for subependymal giant cell astrocytoma: 5-year final analysis |
| Q37232131 | Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex |
| Q36659706 | Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma |
| Q37909448 | Everolimus tablets for patients with subependymal giant cell astrocytoma |
| Q37931887 | Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis |
| Q37025863 | Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas |
| Q48952575 | Freiburg neuropathology case conference: an intraventricular mass lesion. |
| Q38206240 | Genotype/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations |
| Q30470596 | Hereditary Genodermatoses with Cancer Predisposition |
| Q39187306 | Insights into molecular therapy of glioma: current challenges and next generation blueprint |
| Q36063084 | Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study |
| Q36261364 | Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology |
| Q43814142 | Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex |
| Q37644172 | Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide |
| Q38006431 | Molecular therapies for tuberous sclerosis and neurofibromatosis |
| Q92649050 | Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives |
| Q92712142 | Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study |
| Q90448387 | Novel management of glioma by molecular therapies, a review article |
| Q38294226 | Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus |
| Q43927553 | Prevalence of JC polyomavirus genomic sequences from the large T-antigen and non-coding control regions among Bulgarian patients with primary brain tumors |
| Q28078328 | Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy |
| Q35278772 | Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation |
| Q38207541 | Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. |
| Q38014589 | Research and innovation in the development of everolimus for oncology. |
| Q48168842 | Resection of subependymal giant cell astrocytoma guided by intraoperative magnetic resonance imaging and neuronavigation |
| Q33694246 | Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report |
| Q89390888 | Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013 |
| Q38189289 | Subependymal giant cell astrocytoma: current concepts, management, and future directions |
| Q47145272 | Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations |
| Q38150748 | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention |
| Q44136131 | Subependymal nodules and giant cell tumours in tuberous sclerosis complex patients: prevalence on MRI in relation to gene mutation |
| Q43788777 | Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex |
| Q38194055 | Targeted therapy in pediatric low-grade glioma |
| Q38199329 | The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey |
| Q35589678 | The clinical characteristics of subependymal giant cell astrocytoma: five cases |
| Q91955016 | The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas |
| Q47151013 | The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. |
| Q37838317 | The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective |
| Q28070264 | The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors |
| Q39182861 | Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex. |
| Q38792781 | Tuberous Sclerosis Health Care Utilization Based on the National Inpatient Sample Database: A Review of 5655 Hospitalizations |
| Q52327918 | Tuberous sclerosis complex: Concerns and needs of patients and parents from the transitional period to adulthood. |
| Q38297624 | Tuberous sclerosis complex: the past and the future |
| Q39164918 | Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein level |
| Q38798392 | mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology |
| Q37697798 | mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders |
Search more.